Diverse Biochemical Properties of Shp2 Mutants

Mutations in the Src homology 2 (SH2)-containing protein-tyrosine phosphatase Shp2 (PTPN11) underlie half of the cases of the autosomal dominant genetic disorder Noonan syndrome, and somatic Shp2 mutations are found in several hematologic and solid malignancies. Earlier studies of small numbers of mutants suggested that disease-associated mutations cause constitutive (SH2 binding-independent) activation and that cancer-associated mutants are more active than those associated with Noonan syndrome. We have characterized a larger panel of Shp2 mutants and find that this “activity-centric” model cannot explain the behaviors of all pathogenic Shp2 mutations. Instead, enzymatic, structural, and mathematical modeling analyses show that these mutants can affect basal activation, SH2 domain-phosphopeptide affinity, and/or substrate specificity to varying degrees. Furthermore, there is no absolute correlation between the mutants' extents of basal activation and the diseases they induce. We propose that activated mutants of Shp2 modulate signaling from specific stimuli to a subset of effectors and provide a theoretical framework for understanding the complex relationship between Shp2 activation, intracellular signaling, and pathology.

[1]  M. Loh,et al.  Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. , 2004, Blood.

[2]  Jie Wu,et al.  Noonan syndrome–associated SHP2/PTPN11 mutants cause EGF‐dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation , 2004, Human mutation.

[3]  D. Barford,et al.  Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. , 2000, Molecular cell.

[4]  T. Pawson,et al.  The 64-kDa protein that associates with the platelet-derived growth factor receptor beta subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Bruce D Gelb,et al.  PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. , 2002, American journal of human genetics.

[6]  J. Noonan Noonan syndrome revisited. , 1999, The Journal of pediatrics.

[7]  D. Barford,et al.  Visualization of the Cysteinyl-phosphate Intermediate of a Protein-tyrosine Phosphatase by X-ray Crystallography* , 1998, The Journal of Biological Chemistry.

[8]  Xinyang Zheng,et al.  Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase , 1992, Nature.

[9]  Z. Zhao,et al.  A widely expressed human protein-tyrosine phosphatase containing src homology 2 domains. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Michael A. Patton,et al.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.

[11]  J. Kuriyan,et al.  Crystal structures of peptide complexes of the amino-terminal SH2 domain of the Syp tyrosine phosphatase. , 1994, Structure.

[12]  H. Ropers,et al.  Spectrum of mutations in PTPN11 and genotype–phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome , 2003, European Journal of Human Genetics.

[13]  K. Lim,et al.  Targeted disruption of the tyrosine phosphatase PTPα leads to constitutive downregulation of the kinases Src and Fyn , 1999, Current Biology.

[14]  C. Walsh,et al.  Potent Stimulation of SH-PTP2 Phosphatase Activity by Simultaneous Occupancy of Both SH2 Domains (*) , 1995, The Journal of Biological Chemistry.

[15]  B. Neel,et al.  The "Gab" in signal transduction. , 2003, Trends in cell biology.

[16]  B. Neel,et al.  Activated Mutants of SHP-2 Preferentially Induce Elongation of Xenopus Animal Caps , 2000, Molecular and Cellular Biology.

[17]  M. Loh,et al.  SHP-2 and myeloid malignancies. , 2004, Current opinion in hematology.

[18]  B. Gelb,et al.  Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. , 2004, Blood.

[19]  B. Neel,et al.  Tyrosyl Phosphorylation of Shp2 Is Required for Normal ERK Activation in Response to Some, but Not All, Growth Factors* , 2003, Journal of Biological Chemistry.

[20]  M. White,et al.  IRS proteins and the common path to diabetes. , 2002, American journal of physiology. Endocrinology and metabolism.

[21]  C. Walsh,et al.  Activation of the SH2-containing protein tyrosine phosphatase, SH-PTP2, by phosphotyrosine-containing peptides derived from insulin receptor substrate-1. , 1994, The Journal of biological chemistry.

[22]  H. Ohashi,et al.  Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia , 2005, Journal of Human Genetics.

[23]  S. Shoelson,et al.  Crystal Structure of the Tyrosine Phosphatase SHP-2 , 1998, Cell.

[24]  H. Kanegane,et al.  Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. , 2004, The Journal of clinical endocrinology and metabolism.

[25]  B. Marino,et al.  Congenital heart diseases in children with Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canal. , 1999, The Journal of pediatrics.

[26]  M. Loh,et al.  PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group , 2004, Leukemia.

[27]  K. Sharp,et al.  Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons , 1991, Proteins.

[28]  M. Loh,et al.  Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. , 2004, Blood.

[29]  B. Jenkins,et al.  Acquiring signalling specificity from the cytokine receptor gp130. , 2004, Trends in genetics : TIG.

[30]  B. Neel,et al.  Isolation of a src homology 2-containing tyrosine phosphatase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Seripa,et al.  Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes , 2003, Journal of medical genetics.

[32]  C. Walsh,et al.  Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor. , 1993, The Journal of biological chemistry.

[33]  John D. Minna,et al.  Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia , 2004, Cancer Research.

[34]  B. Neel,et al.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. , 2003, Trends in biochemical sciences.

[35]  K. Kosaki,et al.  Somatic PTPN11 mutation with a heterogeneous clonal origin in children with juvenile myelomonocytic leukemia , 2004, Leukemia.

[36]  Michael B Yaffe,et al.  BRCT Repeats As Phosphopeptide-Binding Modules Involved in Protein Targeting , 2003, Science.

[37]  J. Kutok,et al.  Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. , 2005, Cancer cell.

[38]  S. Harrison,et al.  Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2 , 1996, Nature.

[39]  J. Licht,et al.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia , 2003, Nature Genetics.

[40]  B. Kennedy,et al.  Attenuation of Adhesion-dependent Signaling and Cell Spreading in Transformed Fibroblasts Lacking Protein Tyrosine Phosphatase-1B , 2001, The Journal of Biological Chemistry.

[41]  R. Gibbs,et al.  PTPN11 Mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13 , 2002, Human mutation.

[42]  R. Weening,et al.  Noonan's syndrome in association with acute leukemia. , 1995, Pediatric hematology and oncology.

[43]  J Godovac-Zimmermann,et al.  Phosphotyrosine 1173 Mediates Binding of the Protein-tyrosine Phosphatase SHP-1 to the Epidermal Growth Factor Receptor and Attenuation of Receptor Signaling* , 1998, The Journal of Biological Chemistry.

[44]  T Pawson,et al.  Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Sap,et al.  Receptor protein tyrosine phosphatase α activates Src-family kinases and controls integrin-mediated responses in fibroblasts , 1999, Current Biology.

[46]  C. Walsh,et al.  Expression, purification, and characterization of SH2-containing protein tyrosine phosphatase, SH-PTP2. , 1993, The Journal of biological chemistry.

[47]  Charis Eng,et al.  Catalytic specificity of protein-tyrosine kinases is critical for selective signalling , 1995, Nature.